INTRODUCTION
Breast cancers that arise in BRCA1 and BRCA2 mutation carriers are characterized by homologous recombination DNA repair deficiency. The BRCA1 and BRCA2 gene products are critical for DNA double-strand break repair, and as such, DNA repair-targeted therapeutics have been investigated to exploit the inherent homologous recombination deficiency of these tumors to therapeutic advantage. 1 Preclinical studies have demonstrated that BRCA1/2-deficient breast tumors exhibit differential chemosensitivity compared with BRCA1/2-proficient cancers, with greater sensitivity to platinum and gemcitabine and less sensitivity to taxanes. [2] [3] [4] [5] In clinical studies, data have shown high-level activity of cisplatin as neoadjuvant therapy in BRCA1 mutation carriers and poorer response rates and progression-free survival in BRCA1 mutation carriers (compared with noncarriers) with metastatic hormone receptor-negative breast cancer treated with taxane therapy. 6 Sporadic triple-negative breast cancer (TNBC) shares many pathologic and molecular features with breast cancers caused by hereditary BRCA1 germline mutations. 7 On the basis of this and the observations described, the hypothesis emerged that sporadic TNBC may possess similar DNA repair defects and demonstrate similar chemosensitivity profiles as BRCA1 mutation-associated breast tumors. Preclinically, basal-like breast cancer cell lines, like BRCA1-deficient cancer cell lines, demonstrate increased sensitivity to poly (ADPribose) polymerase (PARP) inhibition, cisplatin, and gemcitabine and are deficient in base excision repair, leading to enhanced sensitivity to oxidative DNA damage. 8, 9 Therefore, we set out to investigate a neoadjuvant combination chemotherapy regimen targeting DNA repair defects in early-stage TNBC and BRCA1/2 mutation-associated breast cancers. Specifically, PrECOG 0105 was designed to assess the efficacy and safety of and predictors of response to iniparib (BSI-201; sanofi-aventis, Paris, France) in combination with gemcitabine and carboplatin. Over the course of this study, knowledge regarding the mechanism of action of iniparib evolved. Initially investigated as a PARP1 inhibitor, it was subsequently demonstrated that iniparib does not possess characteristics typical of the PARP inhibitor class.
10-12 Preclinically, the metabolites of iniparib are believed to be involved in the uncoupling of electron transport from oxidative phosphorylation, which in turn produces reactive oxygen species at cytotoxic levels.
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A major goal of this study was to identify markers of response to this neoadjuvant therapy among patients with TNBC. Given the clinical potential of DNA repair-targeted therapeutics, many groups have focused on developing methods to characterize changes in the genomic landscape resulting from underlying homologous recombination defects in cancers.
14-17 In addition to BRCA1 and BRCA2, there are many DNA repair genes that may be altered by germline or somatic mutations, rearrangements, DNA methylation, or dysregulated mRNA expression that are hypothesized to result in impairment of the homologous recombination pathway. The homologous recombination deficiency loss of heterozygosity (HRD-LOH) assay allows for the detection of HRD regardless of etiology or mechanism as measured by levels of genomic LOH.
14 During assay development, LOH regions of intermediate size were observed more frequently in ovarian tumors with defective BRCA1/2. On the basis of this finding, the HRD-LOH assay was developed and represents a count of the number of LOH regions of intermediate size (Ͼ 15 Mb and Ͻ whole chromosome) observed in the tumor genome. In this article, we report the first assessment to our knowledge of the HRD-LOH biomarker in TNBC and evaluate its ability to distinguish responders from nonresponders treated with neoadjuvant platinum-based therapy.
PATIENTS AND METHODS

Patients, Study Design, and Treatment Regimen
This single-arm phase II neoadjuvant study enrolled patients with newly diagnosed, treatment-naive stage I to IIIA (T size Ն 1 cm by magnetic resonance imaging [MRI] ) TNBC (estrogen receptor [ER] Յ 5%, progesterone receptor [PR] Յ 5%, and human epidermal growth factor receptor 2 [HER2] negative [0 or 1ϩ by immunohistochemistry or fluorescent in situ hybridization nonamplified]) or BRCA1/2 mutation-associated breast cancer. A core biopsy of the primary breast tumor was required for research purposes. All patients underwent comprehensive BRCA1 and BRCA2 genotyping.
Patients were treated with carboplatin intravenously (IV) at an area under the curve of 2 on days 1 and 8, gemcitabine 1,000 mg/m 2 IV on days 1 and 8, and iniparib 5.6 mg/kg IV on days 1, 4, 8, and 11 every 21 days before definitive surgery. In the original protocol, patients at Stanford University were treated with four cycles of therapy (total of 13 patients) before the protocol was amended to increase treatment duration to six cycles and expand the trial to multiple centers within PrECOG, with the goal of treating 80 patients with the six-cycle regimen. After completion of surgery, adjuvant systemic therapy and radiotherapy were recommended at the discretion of the treating physician.
This protocol was approved by the institutional review board at each participating center. Informed consent was obtained from all patients.
Study End Points and Statistical Considerations
The primary end point was pathologic complete response (pCR) by central assessment, defined as the absence of invasive carcinoma in the breast and axillary lymph nodes. The extent of residual disease was assessed using the residual cancer burden (RCB) index. 18 This index has been validated as an independent prognostic marker of distant relapse-free survival in patients with breast cancer treated with neoadjuvant chemotherapy (RCB 0, complete pathologic response; RCB I, minimal residual disease; RCB II, moderate residual disease; and RCB III, extensive residual disease). Additional secondary end points included safety of the combination, radiographic response by MRI (central review), rate of conversion to breast conservation eligibility, and correlation of baseline tumor gene expression and gene copy number profiles with treatment response.
Per protocol, the primary analysis was to combine patients enrolled to receive four or six cycles of neoadjuvant therapy. At the time the study was expanded, the revised design was based solely on the patients to be treated with six cycles. Therefore, both the 6-cycle cohort alone and the combined cohorts are reported. The primary analysis included all patients registered with the intent to treat (ITT). Efficacy analyses were performed for all eligible patients and safety analyses for all patients who received at least one dose of trial therapy. Assuming that 76 of 80 patients were eligible and treated, the regimen would be deemed of interest if the lower bound of the 90% exact binomial CI for the pCR rate exceeded 25%. This design had an 87.5% power to detect a 15% absolute improvement in pCR over historical data with cisplatin alone, 19 using a binomial test with a one-sided ␣ level of 5%.
RESULTS
Patient and Tumor Characteristics
A total of 93 patients were treated in the study. Thirteen patients were enrolled onto the four-cycle protocol, and 80 patients were enrolled onto the six-cycle protocol. All patients in the four-cycle group completed treatment. Of the 80 patients in the six-cycle group, 11 (13.8%) discontinued treatment prematurely: five (6.3%) because of progressive disease, five because of unacceptable toxicity (four with wild-type BRCA, one with mutant BRCA), and one because of a protocol violation (patient lost to follow-up with mutant BRCA). There were no ineligible patients, so the ITT and safety populations included the same number of patients.
Patient characteristics are detailed in Table 1 . All enrolled patients were women, and the majority were white (72%). Most patients had clinical stage II breast cancer (72%), and most had TNBC, except for three BRCA1/2 mutation carriers who had ER-positive and/or PR-positive/HER2-negative breast cancer. A total of 19 patients (24%) treated with six cycles had a deleterious germline mutation in BRCA1, BRCA2, or both genes. Sixty-five patients treated with six cycles of therapy had fresh frozen tumor tissue available for gene expression profiling (Affymetrix U133 plus 2.0; Santa Clara, CA), and of these, 78% were basal-like by PAM50 analysis 20 (Data Supplement). Fiftyone of the 65 samples passed the ER filter used by the Vanderbilt TNBC type calculator (http://cbc.mc.vanderbilt.edu/tnbc/), allowing for triple-negative molecular subtype assignment with the following distribution: basal-like 1 (BL1), n ϭ 8 (16%); basal-like 2 (BL2), n ϭ 2 (4%); immunomodulatory (IM), n ϭ 14 (27%); luminal androgen receptor (LAR), n ϭ 4 (8%); mesenchymal, n ϭ 14 (27%); mesenchymal stem-like (MSL), n ϭ 3 (6%); and unstable, n ϭ 6 (12%; Data Supplement).
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Response Data
The primary efficacy results for pathologic response in the ITT population are summarized in Table 2 . Among all 80 enrolled patients treated with six cycles of therapy, 29 patients (36.3%) achieved a pCR. Among those wild type for BRCA1/2, the pCR rate was 33%. Among BRCA1/2 mutation carriers, the pCR rate was 47%, and in BRCA1/2 mutation carriers with TNBC, it was 56%. One BRCA1 mutation carrier had bilateral breast cancer and achieved a pCR in both breasts, although this was counted as one response. Among all 93 patients, 31 (33.3%) achieved a pCR (90% CI, 25.3% to 42.2%). Rates of combined RCB 0/1 are also detailed in these subgroups.
In the six-cycle and combined groups, respectively, 58 (72.5%; 90% CI, 63.1% to 80.6%) and 68 patients (73.1%; 90% CI, 64.5% to 80.6%) achieved an objective response by MRI. Among the 23 and 27 patients not eligible for breast-conservation surgery at baseline in the six-cycle and combined groups, 14 (60.9%; 90% CI, 41.7% to 77.8%) and 15 (55.6%; 90% CI, 38.2% to 72.0%), respectively, became eligible for breast conservation.
Adverse Events
All patients had at least one treatment-emergent adverse event (TEAE). The most common treatment-related TEAEs among all 93 patients and 80 patients treated with six cycles, respectively, were fatigue (84.9% and 85.0%), nausea (81.7% and 81.3%), neutropenia or neutrophil count decreased (49.5% and 53.8), alopecia (46.2% and 51.3%; [grade 2, 4.3% and 5.0%]), anemia (33.3% and 35%), dysgeusia (25.8% and 28.8%), diarrhea (24.7% and 26.3%), and rash (20.4% and 23.8%). All grade 4 TEAEs occurred in patients receiving six cycles of treatment. There were no deaths during the study. Table 3 summarizes all grade 3 to 4 adverse events possibly, probably, or definitely related to the combination treatment regimen. Notably, among 80 patients treated with six cycles of therapy, the rate of grade 2 (complete) alopecia was only 5%, and the rate of grade Ն 2 neuropathy was 1%.
Correlative Studies HRD-LOH. Given the hypothesis of underlying DNA repair defects in sporadic TNBC, we set out to evaluate a novel measure of genomic instability to detect the accumulation of changes in the genomic landscape of a tumor attributable to defective homologous recombination DNA repair. Methods for determination of the HRD-LOH score are detailed in the Appendix (online only).
Among 80 patients treated in the six-cycle protocol, 77 (18 with mutant BRCA1/2) had sufficient DNA extracted from their tumor core biopsies to proceed with the HRD assay (Data Supplement). Of these, 66 samples (17 with mutant BRCA1/2) passed the quality filter based on the level of discrimination between balanced and unbalanced regions of the tumor genome, and 11 did not (including one with mutant BRCA1/2). One BRCA1 mutation carrier was excluded because she had no pathologic outcome data available, leaving 65 patients with HRD-LOH and response data. In total, four somatic mutations were identified in BRCA1 or BRCA2 on tumor sequencing; two of these patients achieved a pCR.
In Figure 1 , the distribution of HRD-LOH scores among responders in blue and nonresponders in gold is depicted. Mean HRD-LOH scores were higher in responders compared with nonresponders (15.7 v 12.5; P ϭ .020; Table 4 ). Importantly, mean HRD-LOH scores were similar in BRCA1/2-mutant versus intact responders. When those with BRCA1/2 germline mutations were excluded, mean HRD-LOH scores in BRCA1/2 wild-type responders were higher than in wild-type nonresponders (16.1 v 12.3; P ϭ .021). When the data were analyzed using a cutoff of Ն 10 as indicative of homologous recombination deficiency, responders were more likely to exhibit HRD-LOH scores Ն 10 compared with nonresponders in all patients and BRCA1/2 wild-type patients (P ϭ .0026 and .0024, respectively). As shown in Figure 2 , rates of favorable pathologic response, defined as RCB of 0 or 1, were 66% versus 20% for patients with an HRD-LOH score Ն 10 compared with Ͻ 10; 81% versus 47% for patients harboring an underlying germline BRCA1/2 mutation compared with wild type; and 66% versus 8% for patients with a high HRD-LOH score or BRCA1/2 mutation compared with patients with a low HRD-LOH score who were also BRCA1/2 wild type, respectively (Fig 2) . When data were analyzed using RCB 0 (pCR) versus no pCR, mean HRD-LOH scores were 16.0 among those with a pCR and 13.4 among those with no pCR (P ϭ .058). When looking at HRD-LOH as a dichotomous variable (Ͻ 10 v Ն 10), patients with a pCR were more likely to exhibit HRD-LOH scores Ն 10 compared with patients who did not achieve a pCR (P ϭ .0012).
In an attempt to better understand the underlying mechanism for a high HRD score and/or clinical response in patients with TNBC without germline or tumor BRCA1/2 mutations, a preliminary analysis of tumor BRCA1 promoter methylation and subsequent gene expression was performed for 25 of 45 BRCA1/2 wild-type patients with HRD-LOH data. In total, 15 samples had BRCA1 promoter methylation, and all had an HRD-LOH score Ն 10. Nine (60%) of 15 were responders (RCB 0 or 1; Data Supplement).
Gene expression. In an exploratory analysis in the six-cycle group, we assessed response by RCB group (0 or 1 v 2 or 3) across the TNBC molecular subtypes. As previously reported, 22 we also observed considerable variation in rates of favorable response across these subtypes, although numbers in some of the groups were small, and results must be interpreted cautiously (Data Supplement). When germline BRCA1/2 mutation status was overlaid on this, we observed that those with mutant BRCA1/2 were distributed across the various subtypes, with only one BRCA-mutant patient in the BL1 and BL2 groups combined. Mean HRD-LOH scores across the TNBC subtypes were as follows: BL1, 17 (range, 2 to 24; n ϭ 8); BL2, 20 (n ϭ 1); IM, 15.9 (range, 6 to 24; n ϭ 10); LAR, 6.7 (range, 5 to 8; n ϭ 3); mesenchymal, 13.1 (range, 6 to 25; n ϭ 14); MSL, 13 (range, 10 to 16; n ϭ 2); and unstable, 10.6 (range, 6 to 17; n ϭ 6). Appendix Table A1 (online only) lists the molecular characteristics of the five patients with progressive disease.
DISCUSSION
The study met its primary end point, with a pCR rate of 36% (90% CI, 27% to 46%) among patients treated with six cycles of therapy and a pCR rate of 33.3% (90% CI, 25.3% to 42.2%) in all patients. Given the nonrandomized nature of this study, the relative contribution of iniparib therapy cannot be assessed. Nevertheless, this platinum-based, non-anthracycline-and non-taxane-based regimen was well tolerated and produced pathologic responses that were on par with those recently reported with third-generation anthracycline/taxane-based regimens (pCR, 26% to 39%). 23, 24 In molecularly defined subgroups of our TNBC cohort selected for DNA repair deficiencies using BRCA1/2 mutation status and/or the HRD-LOH assay, we observed favorable pathologic response rates (RCB, 0 or 1) Ն 65%, supporting the targeted nature of the therapy. Our results do not have direct impact on clinical practice today, but they strongly suggest that patient selection based on underlying DNA repair deficiency in future randomized trials of standard versus DNA repair defect-targeted therapy in TNBC should be pursued.
A strength of this study is the comprehensive molecular phenotyping that was performed on all patient tumors. Microarray gene expression analysis confirmed that the majority of patients selected for triple-negative status based on immunohistochemical characterization were basal-like (78% by PAM50). Further subtyping using the Vanderbilt gene expression criteria suggest that some patients with TNBC may exhibit particular chemosensitivity (IM and MSL groups), whereas others are more resistant (LAR) and that these differences are not directly related to BRCA1/2 germline mutation status.
This study also comprehensively evaluated BRCA1/2 germline mutation status of all enrolled patients as well as pretreatment tumor biopsy samples for BRCA1/2 mutations and a measure of genomic instability using a novel diagnostic approach. The pCR rate with this platinum-based regimen was highest in patients with germline BRCA1/2 mutations, although comparisons in our study were underpowered. Among patients lacking a germline BRCA1/2 mutation, the HRD-LOH assay was able to identify additional patients with sporadic TNBC and an elevated HRD-LOH score associated with underlying defects in homologous recombination who achieved a favorable pathologic response. Therefore, the HRD-LOH assay seems to be a powerful diagnostic tool for assessing DNA repair capacity of tumors, as reflected by a so-called genomic scar, without knowledge of an underlying genetic cause and without the need for assessing a DNA damage-inducible response to therapy (eg, gamma-H2AX focus formation). Prospective evaluation of the HRD-LOH assay is necessary to confirm whether this biomarker is prognostic or truly predictive of therapeutic benefit to DNA-damaging therapy such as platinum as well as newer-generation PARP inhibitors. The molecular mechanism for HRD in our patients with TNBC without a BRCA1/2 mutation is not known, but epigenetic downregulation of BRCA1 expression secondary to promoter methylation may explain this in part.
Whether the carboplatin and gemcitabine backbone of our regimen represents an improved therapy for the HRD-selected patients with TNBC in our trial, or whether these patients simply respond better to any cytotoxic regimen, cannot yet be assessed. To date, the results of three randomized neoadjuvant TNBC platinum studies have been reported, all of which examined an add-on approach of carboplatin to anthracycline-and taxane-based therapy. The GEICAM (Grupo Español de Investigación en Cáncer de Mama) 2006-03 study of epirubicin and cyclophosphamide followed by docetaxel with or without carboplatin showed no improvement in pCR with the addition of carboplatin. 25 In the phase II GeparSixto trial, which assessed a regimen of dose-intense anthracycline-and taxane-based chemotherapy with bevacizumab with or without carboplatin, patients receiving carboplatin achieved a pCR rate of 53.2% compared with 36.9% in patients who did not. 26 In the phase II CALGB 40603 (Cancer and Leukemia Group B) study of standard anthracycline/taxane-based chemotherapy with or without carboplatin and with or without bevacizumab, the addition of carboplatin significantly increased the pCR rate (breast and axilla) in the per-protocol population by 13% (pCR with carboplatin, 54% v without, 41%). 23 Toxicity was increased and early discontinuation was more common in carboplatintreated patients.
Placing these results, along with the results of the GeparSixto and CALGB 40603 studies, in the broader context deserves careful consideration. In the conduct of PrECOG 0105, we found that certain toxicities commonly encountered with anthracycline/taxane-containing adjuvant therapy, specifically alopecia (grade 2, 5%), chemotherapyinduced amenorrhea, and peripheral neuropathy (grade 2, 1%; grade 3 to 4, 0%), were infrequent. In a randomized setting, we would expect that important differences in toxicity would be observed among patients treated with gemcitabine and carboplatin compared with a regimen such as paclitaxel and carboplatin followed by doxorubicin and cyclophosphamide. These toxicity differences are important and may affect endocrine symptom burden, reproductive concerns, and overall quality of life in this group of predominantly young, premenopausal breast cancer survivors.
In summary, our data from PrECOG 0105 support the notion that understanding the biology of TNBC and BRCA1-and BRCA2-mutant breast cancer allows for improved therapeutic strategies that target the DNA repair defects of these tumors. Future trials with treatment selection based on tumor DNA repair capacity in TNBC are currently in development and may lead to improved long-term outcomes.
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